Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports
Reuters
Yesterday
Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports
Feb 23 (Reuters) - Drugmaker Merck MRK.N is separating its human-health business into two divisions to offset pressures related to the patent loss of its top-selling drug Keytruda, the Wall Street Journal reported on Monday.
One division will house its cancer drugs, including Keytruda, while the other will sell its non-cancer products.
Merck did not respond to a Reuters request for comment immediately.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.